首页> 外文期刊>Drug Safety - Case Reports >Muscle Injury After Intramuscular Administration of Diclofenac: A Case Report Supported by Magnetic Resonance Imaging
【24h】

Muscle Injury After Intramuscular Administration of Diclofenac: A Case Report Supported by Magnetic Resonance Imaging

机译:肌内注射双氯芬酸后的肌肉损伤:磁共振成像支持的一例报道

获取原文
       

摘要

Intramuscular injection of diclofenac is still frequently practiced, although there is ample evidence that the risk of local tissue intolerability is highly underestimated. The aim of this study was to evaluate local toxicity in a patient using magnetic resonance imaging. A patient who gave written informed consent received a medically indicated intramuscular administration of diclofenac 75?mg/2?mL. Simultaneously with magnetic resonance imaging of the depot, a clinical–chemical evaluation and quantification of diclofenac in plasma was performed. A manifold enhancement of the T2-weighted magnetic resonance signal was observed in a muscle area of approximately 60?mL volume, with maximum signal intensity 30?min after injection, the time of maximum diclofenac plasma exposure. Plasma creatine kinase activity was elevated approximately sixfold within 8?h and normalized within 1?week, whereas the magnetic resonance enhancement disappeared within 5?weeks. Interestingly, the patient did not complain about any clinical symptoms at the injection site. Asymptomatic tissue injury after intramuscular injection of diclofenac, caused by intramuscular dosing, can be reliably evaluated by magnetic resonance imaging and should be applied early during the development of parenteral dosage forms. Clinical Trials Registration Number : BB130/16 (Ethics Committee of the University Medicine Greifswald).
机译:尽管有充分的证据表明高度估计了局部组织不耐受的风险,但仍经常进行肌内注射双氯芬酸。这项研究的目的是使用磁共振成像评估患者的局部毒性。给予书面知情同意的患者接受了医学上指示的双氯芬酸75?mg / 2?mL的肌肉注射。在对该仓库进行磁共振成像的同时,还进行了血浆中双氯芬酸的临床化学评估和定量。在大约60?mL体积的肌肉区域观察到T2加权磁共振信号的多种增强,注射后30分钟(最大双氯芬酸血浆暴露时间)的最大信号强度出现。血浆肌酸激酶活性在8小时内升高约六倍,并在1周内恢复正常,而磁共振增强在5周内消失。有趣的是,患者在注射部位没有任何临床症状。肌内注射引起的肌肉注射双氯芬酸后无症状的组织损伤,可以通过磁共振成像可靠地评估,应在肠胃外剂型开发过程中尽早应用。临床试验注册号:BB130 / 16(格赖夫斯瓦尔德大学医学伦理委员会)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号